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Mucosal-associated invariant T (MAIT) cells are an innate-like T-cell population involved in
anti-bacterial immunity. In human beings, MAIT cells are abundant, comprising ~10% of the
CD8+ T-cell compartment in blood. They are enriched at mucosal sites and are particularly
prevalent within the liver. MAIT cells are defined by the expression of a semi-invariantT-cell
receptor (Vα7.2-Jα33/12/20) and are restricted by the non-polymorphic, highly evolutionar-
ily conserved MHC class Ib molecule, MHC-related protein (MR)1. MR1 has recently been
shown to present an unstable pyrimidine intermediate derived from a biosynthetic precur-
sor of riboflavin; riboflavin biosynthesis occurs in many bacteria but not in human beings.
Consistent with this, MAIT cells are responsive to riboflavin-metabolizing bacteria, includ-
ing Salmonella. In mouse models, MAIT cells have been shown to play a non-redundant
role in anti-bacterial immunity, including against Escherichia coli, Klebsiella pneumoniae,
and Mycobacterium bovis BCG. In human beings, MAIT cells are decreased in frequency
in the blood of patients with tuberculosis or pneumonia, and their frequency has been
inversely correlated with the risk of subsequent systemic bacterial infection in patients in
intensive care. Intriguingly, MAIT cells are also depleted from the blood early in HIV infec-
tion and fail to recover with anti-retroviral therapy, which may contribute to the susceptibility
of patients infected with HIV to certain bacterial infections, including non-typhoidal Salmo-
nella. In this review, we will discuss what is currently known about MAIT cells, the role
that Salmonella has played in elucidating MAIT cell restriction and function, and the role
MAIT cells might play in the control of Salmonella infection.
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INTRODUCTION
In 1999, Tilloy et al. first described mucosal-associated invariant
T (MAIT) cells (1). Interest in this unique subset of innate-
like T-cells has increased rapidly over the last 5 years as novel
findings have revealed their unique anti-bacterial function and
phenotype (2, 3). MAIT cells represent the most abundant
innate-like T-cell population within human beings, comprising
up to ~5% of the total T-cell population; this compares with
just ~0.1% for invariant natural killer T (iNKT) cells (4, 5).
They are characterized by the expression of a semi-invariant
TCR (Vα7.2-Jα33/12/20) that recognizes the evolutionarily con-
served MHC-like protein 1 (MR1), which presents a bacterial-
derived ligand (6–11). Although they can be activated through
their TCR, they are also readily stimulated by innate cytokines,
either leading to the expression of pro-inflammatory cytokines
or the release of cytotoxic and pro-inflammatory granzymes
(Figure 1) (12, 13). Furthermore, MAIT cells have been asso-
ciated with a number of disease settings, including bacterial
infections (14), and pro-inflammatory diseases such as multiple
sclerosis (15) and psoriasis (16). Thus, this large T lympho-
cyte population is likely to have an important role in human
health.
This review will explore what is currently known about MAIT
cells in human beings. Comparisons between human and murine
MAIT cells have been made elsewhere (4). Furthermore, we will
discuss the role that Salmonella has played in identifying the func-
tions of this cell type, and the potential role MAIT cells may have
in controlling Salmonella infections.
MAIT CELL PHENOTYPE
In addition to possessing the Vα7.2-Jα33/12/20 TCR, MAIT cells
can be identified in human beings by the expression of a charac-
teristic phenotypic signature composed of a number of additional
surface and transcriptional markers.
MEMORY PHENOTYPE
In adults, MAIT cells typically express an effector memory pheno-
type: CD45RO+, CCR7−, CD62L−, CD27+, and CD28+ (17–19).
However, in cord blood, MAIT cells possess a naïve phenotype
(CD45RA+, CCR7+, CD62L+), but still retain a phenotypic sig-
nature characteristic of adult MAIT cells, including the expression
of CD161, interleukin (IL)-18Rα, CD8αα, and CCR6 (3, 5, 17,
20). A recent study demonstrated that MAIT cells in the thymus,
spleen, and mesenteric lymph nodes of aborted second trimester
fetuses also had a naïve phenotype and expressed only low levels of
the characteristic MAIT cell markers, such as IL-18Rα and CD8αα,
while MAIT cells in the fetal intestine, liver, and lung had a more
memory phenotype (21).
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FIGURE 1 | Potential MAIT cell response to Salmonella infected cells.
(1) Internalization of Salmonella by an antigen-presenting cell, either through
infection or actively by phagocytosis. (2) Lysis of the bacteria, within
endocytic compartments, releases 5-A-RU, which is converted to 5-OE-RU or
5-OP-RU and binds to and stabilizes MR1. (3) The stable MR1 translocates to
the cell surface, where it is presented along with other co-stimulatory
molecules, e.g., CD80 or CD86. (4) Bacterial components trigger pathogen
recognition receptors (PRR), such as TLR8. (5) PRR triggering drives cytokine
expression, such as IL-12, and the activation of the inflammosome, resulting
in the release of active-IL-18. (6) MAIT cells are activated either by TCR
recognition of MR1 in combination with co-stimulatory receptors, e.g., CD28,
and/or by cytokines, e.g., IL-12 and IL18. (7) Activated MAIT cells express
pro-inflammatory cytokines, e.g., IFNγ, TNFα, and IL-17. (8) These cytokines
can directly act anti-bacterially, or recruit and stimulate other immune cells,
e.g., neutrophils by IL-17. (9) Activation of MAIT cells upregulates perforin and
granzyme B expression. (10) Theoretically, the degranulation of cytotoxic
granules into infected cells (target cells), via recognition of MR1, could induce
cell death and, thus, the potential clearance of infected cells.
CD161
CD161 is a C-type lectin-like receptor originally identified by
Lanier et al. (22). It is found on a broad range of lymphocytes,
including CD4+, CD8+, γδ+ T-cells, and NK cells. The majority
of NK cells express CD161 (>90%), while in the CD4+, CD8+,
and γδ+ T-cell subsets, CD161 expression is limited to ~30% of
cells (19, 23). However, within the CD8+ and CD8− CD4− T-
cell population, CD161 expression can distinguish three separate
subsets, CD161−, CD161intermediate/+, and CD161high/++; MAIT
cells populate the CD161++ subset (17, 18). In adult peripheral
blood, MAIT cells represent ~85% of the CD161++ subset (24).
However, in cord blood, the MAIT cells make up a much smaller
proportion of this subset, averaging ~15% of the CD161++ CD8+
T-cell population (21, 25, 26). During early childhood, this pop-
ulation expands so that by the age of 24 months the MAIT cell
population already represents ~50% of the CD161++ CD8+ T-cell
population (25).
The function of CD161 on MAIT cells is yet to be fully eluci-
dated. On NK cells, binding of CD161 to its ligand [lectin-like
transcript (LLT) 1] leads to an inhibition of cytotoxicity (27–
29). Two studies explored the role of CD161 on CD8+ T-cells
and reached opposing conclusions (27, 29). Rosen et al. found
that cross-linking CD161 had no effect on anti-CD3/CD28 stim-
ulated CD8+T-cells in terms of IFNγ expression and inhib-
ited TNFα expression, whereas Aldemir demonstrated increased
IFNγ expression after CD161 signaling. Le Bourhis et al. recently
reported that ligation of CD161 on MAIT cells inhibited cytokine
production but had no effect on cytotoxicity (30). One explana-
tion for these differences could be due to the different CD161
cross-linking antibody clones used.
CD161 surface expression has recently been reported to be
downregulated after long-term activation in vitro; downregulation
was associated with greater rounds of proliferation (13). In HIV
infection, loss of expression of CD161 by MAIT cells has been sug-
gested (31). Given that MR1-tetramer-positive cells are not found
in the CD161-negative population in healthy individuals (8), this
requires further investigation.
IL-18Rα
CD161 expression is associated with high levels of IL-18Rα
expression. Of all human T lymphocytes, MAIT cells express
the highest level of IL-18Rα (12, 17). Naïve MAIT cells, derived
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from cord blood, have also been shown to be IL-18Rα+ (5, 24).
Recent observations of tissue from second trimester fetuses suggest
that IL18Ra expression is low upon egress from the thymus but
increases as MAIT cells mature in the tissues (21). Expression of
IL-18Rα conveys an ability to respond robustly to cytokine stim-
ulation (discussed below), which is limited in the other human
T-cell populations (12).
ZBTB16
The development of MAIT cells parallels that of NKT cells. Both
innate-like T-cell subsets are selected for by non-classical MHC
molecules, MR1 and CD1d, respectively, expressed on double
negative thymocytes (32), and both subsets also express the tran-
scription factor ZBTB16 (33). However, while NKT cells exit the
thymus as an expanded and mature population, MAIT cells do not.
Instead, murine models have shown that MAIT cells within the
periphery have a naïve and immature phenotype, lacking expres-
sion of ZBTB16, CD25, CD69, or ICOS and further require an
established microbiota and B-cells to expand into a memory phe-
notype (33). In contrast, MAIT cells found in the periphery of
human fetuses have already acquired a more mature, memory
phenotype, expressing ZBTB16, IL-18Rα and, upon bacterial stim-
ulation, the capacity to express IFNγ and, in cells from the small
intestines, IL-22 (5, 21). What drives selection and maturation
in utero is unclear, but suggests that an endogenous ligand for
MR1 may exist. Alternatively, this may reflect in utero exposure to
commensal microflora, as has recently been suggested (34–36).
RORγT
CD161 expression is also a key phenotypic maker of IL-17 secreting
cells (19, 37). Within the CD4+T-cell subset, Th17 cells repre-
sent a novel helper cell population that can secrete IL-17A under
the control of the master transcription factor retinoic acid-related
orphan receptor (ROR) γt (38, 39). Within the CD8+T-cell subset,
the expression of RORγt and the secretion of IL-17 are restricted
to Tc17 cells that are CD161++. Thus, MAIT cells represent the
vast majority of Tc17 cells (17, 24). The ability of MAIT cells to
express IL-17A has recently been shown to depend on their pre-
exposure to cytokines IL-1beta, IL-23, and IL-7 (40). Interestingly,
hepatic stromal cells constitutively express IL-7, emphasizing the
link between MAIT cells and the liver (41, 42).
CO-RECEPTOR USAGE
CD161++/MAIT cells also encompass the CD8alpha/alpha popu-
lation in adult blood, small bowel, and liver (5). Interestingly, this
population is not seen in cord blood, or fetal thymus, but is seen
at low levels in fetal intestine, liver, and lung (21), suggesting that
it is derived from the CD8alpha/beta population through the reg-
ulation of CD8beta. Functionally and phenotypically, there is no
difference between the CD8alpha/alpha and CD8alpha/beta sub-
sets of the CD161++/MAIT cell population (5). However, Walker
et al. have also described the expression of CD8alpha/alpha as the
marker of terminally differentiated CD8+ T-cells that can be found
in a number of chronic viral infections (26).
MULTIDRUG RESISTANCE TRANSPORTER ABCB1
Mucosal-associated invariant T-cells express the ATP-binding cas-
sette (ABC) B1 drug resistance transporter, which can also be seen
on CD161+T-cells to a more limited degree (43). The ability to
efflux drugs has been shown to allow MAIT cells to persist during
chemotherapy for the treatment of acute myeloid leukemia (AML)
or breast cancer (24, 43). The expression of the ABCB1 transporter
possibly reflects the diverse environmental toxins MAIT cells are
exposed to in their niche, although its overall role is not defined.
CHEMOKINE RECEPTOR EXPRESSION
Mucosal-associated invariant T-cells express a range of chemokine
receptors (CCR6, CCR5, CCR9, and CXCR6) that localize them to
the gut, but more prominently to the lungs and liver (24, 44). The
liver receives 25% of its blood supply from the hepatic artery and
75% from the portal vein. The portal vein delivers blood direct
from the gastrointestinal track and spleen, placing the liver in the
front line in the defense against microbial infection. Moreover,
Balmer et al. recently described the liver as a firewall against infec-
tion from commensal bacteria that have invaded the body through
either the intestines or systemic vascular circuits (45). Therefore,
given their anti-bacterial function, it is unsurprising that MAIT
cells represent up to 45% of all liver lymphocytes (24, 40). Fur-
thermore, both CD161+ CD4+ and CD161+CD8+ T-cells are
selectively recruited to the liver during inflammation (17, 23, 40).
ANTI-BACTERIAL ACTIVITY OF MAIT CELLS
Two studies in 2010, by Gold et al. and Le Bourhis et al., observed
that MAIT cells could recognize antigens derived from a range
of bacteria presented on antigen presenting cells (APCs) (2,
25). Gold et al. observed that a large population of CD8+ T-
cells able to respond to Mycobacterium tuberculosis (Mtb) was
present even in unexposed individuals. Functional and pheno-
typic analysis showed that this population was MR1 restricted and
expressed the TCR Vα7.2 chain, i.e., MAIT cells. Furthermore, they
showed that MAIT cells responded to Salmonella enterica serovar
Typhimurium-infected dendritic cells, as well as Escherichia coli
and Staphylococcus aureus. Le Bourhis et al. demonstrated the
ability of MAIT cells to recognize and be activated by monocytes
exposed to E. coli in an MR1-dependent manner. Furthermore,
they observed that MAIT cells are activated by a wide range of
bacteria (E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa,
Lactobacillus acidophilus, Staphylococcus aureus, Staphylococcus
epidermidis, and Mycobacterium abscessus) but not by all (Ente-
rococcus faecalis, Streptococcus pyogenes). In addition, they showed
activation in response to some yeasts (Candida albicans, Candida
glabrata, and Sacchromyces cerevisiae). Moreover, MAIT cells were
not observed in germ-free mice or in germ-free mice repopulated
with E. faecalis, but were in germ-free mice repopulated with Enter-
obacter cloacae or L. acidophilus, underscoring the important role
of certain bacterial species in MAIT cell development.
The ability of MAIT cells to control bacterial infections was
elegantly demonstrated by Georgel et al. through the use of
luminescent-K. pneumoniae (46). Despite the low frequency of
MAIT cells in common laboratory strains of mice, they showed
that in the absence of MR1, and, therefore, MAIT cells, mice suc-
cumbed to disseminated infection, while wild-type mice cleared
the infection within 2 days. No defect in clearance was seen with E.
coli, Shigella dysenteriae, or Yersinia enterocolitica suggesting that
redundancy in the immune response is sufficient to control the
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dissemination of these organisms. In contrast, enhanced control
of E. coli infection and M. abscessus infection was demonstrated
in Vα19 or Vβ6 transgenic mice, which have an increased fre-
quency of MAIT cells, on a MR1 replete background compared
with a MR1−/− background. Subsequent studies by Chua et al. and
Meierovics et al. have demonstrated the need for MAIT cells in the
early control of Mycobacterium bovis, BCG,and Francisella tularen-
sis following a mucosal challenge (47, 48). Moreover, the presence
of MAIT cells had a strong influence on the timing of recruitment
and activation of conventional T-cells, and provided long-term
protection alongside a conventional T-cell response (48).
THE MHC-RELATED PROTEIN (MR)1 AND ITS LIGAND
The broad range of bacteria MAIT cells can respond to was recently
explained with the identification of the ligand that binds MR1
(49). Kjer-Nielsen et al. discovered the structure of MR1 and
the nature of the ligand that it binds after their serendipitous
finding that 6-formyl pterin (6-FP), a photodegradation prod-
uct of folic acid that was present in tissue culture media, was able
to bind to MR1 and allowed its refolding. However, while 6-FP
was able to stabilize the MR1 molecule, it was unable to acti-
vate MAIT cells. Given that the culture supernatant of S. enterica
serovar Typhimurium was able to activate MAIT cells, they rea-
soned that it must contain the activating ligand. Therefore, they
refolded MR1 with the culture supernatant of S. enterica serovar
Typhimurium grown in minimal media that lacked vitamins (M9
minimal media), and analyzed the refolded MR1 by mass spec-
trometry. They observed a single ligand with a mass to charge
ratio (m/z) of 329.11. This was consistent with the ligand being
reduced 6-hydroxymethyl-8-d-ribityllumazine (rRL-6-CH2OH),
a metabolic by-product of riboflavin metabolism. Chemical syn-
thesis of reduced rRL-6-CH2OH confirmed that it had the same
m/z as the ligand identified in the culture supernatant. Fur-
thermore, synthetic reduced rRL-6-CH2OH, as well as related
compounds derived from riboflavin metabolism, 7-hydroxy-6-
methyl-8-d-ribityllumazine (RL-6-Me-7-OH) and 6,7-dimethyl-
8-d-ribityllumazine (RL-6,7-diMe), were able to activate primary
MAIT cells. This pivotal discovery was consistent with the prior
observation that MAIT cells could be activated by Salmonella,
along with other Enterobacteriaceae, P. aeruginosa, S. aureus, and
some yeast species, which all contain the riboflavin synthetic path-
way, but not by S. pyogenes or E. faecalis, which lack the riboflavin
synthetic pathway (2, 25).
As the origin of the previously identified ligand, rRL-6-
CH2OH, was not clear, Corbett et al. derived various strains of
Lactococcus lactis with different mutations in the riboflavin syn-
thesis operon and assessed their ability to activate MAIT cells
(50). Mutants lacking genes involved in the riboflavin synthe-
sis pathway (ribA and ribG) were unable to activate MAIT cells,
and the MR1-binding ligand (m/z 329.11) was undetectable. By
contrast, no defect in MAIT cell activation was seen with ribB
and ribH mutants, pinpointing the production of 5-amino-6-d-
ribitylaminouracil (5-A-RU), an early intermediate in riboflavin
synthesis. The importance of 5-A-RU was confirmed by the
lack of MAIT cell activation and absence of the MR1-binding
ligand (m/z 329.11) in the culture supernatant of S. enterica
serovar Typhimurium SL1344 with mutated ribD and ribH genes;
furthermore, complementation restored reactivity. Despite the
necessity for 5-A-RU, it was unable to bind MR1 or activate MAIT
cells directly. However, upon non-enzymatic condensation with
glyoxal or methylglyoxal, byproducts of other metabolic pathways
(including glycolysis), 5-A-RU formed unstable intermediates [5-
(2-oxoethylideneamino)6-d-ribitylaminouracil (5-OE-RU) and
5-(2-oxopropylideneamino)-6-d-ribitylaminouracil (5-OP-RU)],
which were able to covalently bind to MR1. Furthermore, these
unstable intermediates formed reversible covalent Schiff base com-
plexes with Lys43, analogous to 6-FP (49). Moreover, 5-OE-RU
and 5-OP-RU could be demonstrated in the culture supernatant
of activating bacteria, but not of non-activating bacteria, and could
be captured by MR1. Therefore, MR1 captures unstable interme-
diates that would otherwise convert to lumazines. MR1 refolded
with 5-A-RU and methylgyoxal (5-OP-RU) produced a mass spec-
trometry peak of m/z 329.11, consistent with what was originally
found in Salmonella supernatant (49). This suggested that 5-OP-
RU, and not reduced rRL-6-CH2OH, was the true ligand for MR1.
In support of this hypothesis, they also found a 315.09 m/z species
(corresponding to 5-OE-RU) bound to MR1 refolded in the pres-
ence of E. coli DH5α; the 315.09 m/z species was also detected
with Salmonella, but was much less abundant. This interesting
finding demonstrates that different bacteria may produce different
MAIT-activating ligands.
Overall, our current understanding of this complex process is
that bacterially derived 5-A-RU is converted to 5-OE-RU or 5-
OP-RU by reaction with bacterial or host-derived metabolites.
These unstable intermediates covalently bind to, and stabilize
MR1, which can then be recognized by the MAIT cell TCR.
Recently, Eckle et al. published that MAIT cells activation
can be competitively inhibited by a novel MR1 ligand, acetyl-6-
formylpterin (Ac-6-FP) (51). Ac-6-FP was identified in a search
for analogs of 6-FP that were stronger antagonists of MAIT cell
activation. MR1 efficiently refolded in the presence of Ac-6-FP
and increased surface expression was seen in an MR1-transduced
cell line treated with Ac-6-FP. Neither Ac-6-FP-MR1 tetramers nor
6-FP-MR1 tetramers were able to stain PBMCs. Consistent with
antagonist activity, Ac-6-FP strongly inhibited the activation of
the Jurkat.MAIT cell line in response to the agonist ligands, rRL-
6-CH2OH and 5-OP-RU. Therefore, Ac-6-FP will be a useful tool
in future studies of MAIT cell function.
THE MAIT CELL TCR
The defining feature of MAIT cells is the expression of a semi-
invariant TCR, Vα7.2Jα33/12/20, which restricts MAIT cells to the
evolutionarily conserved, non-polymorphic MHC-related protein
1 (MR1) (1, 6, 9, 11, 44). Vbeta chain usage does vary; however,
it is dominated by Vβ2 and Vβ13.2 (1, 9, 11). Homologous TCRs
have also been identified in mice (Vα19Jα33, paired with Vβ6 or
Vβ8) as well as cattle (1, 5, 52).
The structure of the MAIT cell TCR and the residues that are
critical for interacting with ligand-bound MR1 were determined
prior to identification of the MAIT cell ligand (9, 11). Analysis of
the MAIT cell TCR structure demonstrated that the CDR3α region
is composed of the Vα7.2 and Jα33 of the alpha chain. S. enterica
serovar Typhimurium was used as the source of the MR1-binding
ligand to show individual residues in Vα7.2 (in CDR1α Gly28α
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and Asn30α, in CDR2α Tyr48α, and in CDR3α Asp92α, Asn94α,
and Tyr95α), but not the Vβ chain, made critical contacts with
MR1. However, switching the entire CDR3β loop with one from
a non-MAIT cell TCR abolished recognition of MR1. A similar
pattern was observed with other bacteria (E. coli, K. pneumoniae,
P. aeruginosa, and S. epidermidis). Given the wide specificity, the
authors suggested that the MAIT cell TCR was like a pattern recog-
nition receptor. By mutational analysis, they identified residues
Leu65 and Glu158 on MR1 as critical for the interaction with the
TCR. These two residues mapped centrally to opposite sides of the
antigen-binding cleft of MR1.
The identification of the ligand paved the way for the develop-
ment of MR1 tetramers for the identification of MR1-restricted
T-cells (8) . Reantragoon et al. used MR1 with a K43A mutation
to make tetramers. MR1 K43A could be refolded in the absence of
ligand and once refolded was able to be loaded with reduced rRL-
6-CH2OH. To further prove that the MR1-tetramer was specific
to MAIT cells, PBMCs were depleted of MR1-tetramer binding
cells and tested for reactivity to S. enterica serovar Typhimurium
supernatant or to reduced rRL-6-CH2OH.
Using the loaded tetramers, Reantragoon et al. confirmed that
the majority of MR1-restricted T-cells express the canonical semi-
invariant T-cell receptor, Vα7.2-Jα33, but also identified minor
(8–31%) MAIT cell populations exist that express Vα7.2-Jα12 and
Vα7.2-Jα20. Interestingly, all alpha chains contained the conserved
Tyr95α within CDR3α loop, which forms a hydrogen bond with
RL-6-Me-7-OH bound by MR1 and is crucial for MAIT cell acti-
vation (8, 53). Interestingly, non-canonical TCRs showed a bias
in Vβ usage toward TRBV6-4. Both canonical and non-canonical
TCRs appeared to have the same ligand specificities. MR1-tetramer
staining of lymphocytes isolated from the jejunal mucosa con-
firmed that MAIT cells are enriched at this site, with ~60% of
CD3+ CD4-cells being MAIT cells. Furthermore, the majority
of the tetramer positive cells in the jejunum were shown to be
Vα7.2-Jα33, as in blood. This suggests that frequency of MAIT cells
varies in different anatomical locations within the gastrointestinal
tract, with higher frequencies in jejunum (8) than in ileum (54),
colon, and rectum (31, 55). Alternatively, the variations observed
in MAIT cell frequency in different tissues may reflect differences
in methodology between studies.
Using a mouse MR1 tetramer in a MAIT-enriched mouse
model (transgenic for Vα19 on Cα−/− background), the differ-
ences between mouse MAIT cells and human MAIT cells were
highlighted (8). While human MAIT cells were predominantly
CD8+ with some double negative cells and only a small CD4+
subset, in Vα19-transgenic mice>40% of MAIT cells were CD4+,
with the remainder mostly DN rather than CD8+. Whether this
reflects functional differences between human and mouse MAIT
cells remains to be determined.
A recent study by Gold et al. investigated the TCR usage of
MAIT cells that were responsive to different microbes (56). CD8+
T-cells from healthy donors were stimulated ex vivo with A549 cells
infected with Mycobacterium smegmatis, Salmonella typhimurium,
or C. albicans. Vα7.2+ CD8+ T-cells that produced TNFα were
sorted and their TCR usage determined. They found greater diver-
sity in the TRAJ gene usage than previously reported; while
TRAJ33 dominated, a range of other TRAJ genes were identified,
including some (TRAJ9 and TRAJ39) that do not encode for the
Tyr95a residue that has been reported to be critical for MAIT
cell activation (8, 11, 52). However, as the authors note, there is
no allelic exclusion at the TRA locus, so the non-canonical TRAJ
genes identified may not contribute to the functional MAIT cell
TCR. TRAJ usage and CDR3α sequence of the responding MAIT
cells differed between microbes; there was more similarity in the
CDR3α sequence in MAIT cells activated by the same microbe
than with those activated by a different microbe. Furthermore,
there was significant diversity in TRBV gene sequences of MAIT
cells responding to different microbes, although there was mini-
mal overlap in the CDR3β sequence across donors and microbes.
Overall, this suggested that different MAIT cells respond to differ-
ent microbe-derived ligands. In support of this, of four MAIT
cell clones that were robustly activated by M. smegmatis, only
two were activated by RL-6,7-diMe. The authors speculate that
MR1 ligand diversity drives MAIT cell TCR diversity and that
that the Vα chain primarily mediates contact with MR1, while the
CDR3β chain, positioned above the MR1 ligand-binding groove,
contributes to ligand discrimination, as previously described by
López-Sagaseta et al. (57, 58). This is consistent with the findings
of Eckle et al., who showed that the novel inhibitory MR1 ligand,
Ac-6-FP, induced structural alterations in MR1, which prevented
the MAIT cell TCR CDR3β chain from binding (51). These two
studies open up the exciting possibility that a wide range of novel
MR1 ligands exists, which could modulate the MAIT cell response.
MAIT CELL ACTIVATION
A number of studies have suggested adult MAIT cells to be ter-
minally differentiated and, as a result, less responsive to TCR
signaling, showing low IFNγ production and little proliferation
compared to stimulation that bypasses the TCR (such as activa-
tion by PMA and ionomycin, or PHA) (24, 33, 43). In contrast,
MAIT cells derived from cord blood or fetal tissues readily prolif-
erate with TCR stimulation (21, 33). This lack of responsiveness by
adult MAIT cells to TCR stimulation can, however, be overcome.
Turtle et al. demonstrated that TCR signaling required the addi-
tion of an innate signal/s from either the co-receptor CD28 or the
cytokine IL-12 in order to induce high levels of IFNγ and strong
proliferation (20). Using transcriptional profiling, they went on
to show that the mechanisms controlling TCR signaling in MAIT
cells were distinct from those seen in anergic or exhausted T-cells.
A study by Chua et al. demonstrated that in a murine model
of bacterial infection using M. bovis BCG, IL-12 signaling, but not
TCR signaling, was required for the control of infection; blockade
of IL-12 but not MR1, inhibited the anti-bacterial activity of MAIT
cells (47). This regulation of activation is similar to that seen in
iNKT cells, where IL-12 signaling dominates over CD1d-induced
TCR signaling (59, 60). In human models of MAIT cell activa-
tion, there is a dual role for TCR- and cytokine-induced activation
of MAIT cells. At early time points, 5 hours after a MAIT cell
encounters an antigen-presenting cell (APC) presenting its cog-
nate antigen on MR1, TCR signaling dominates activation (12).
However, at later time points (20 hours), cytokine-mediated acti-
vation is equally important and MR1 blockade has a more limited
effect. In contrast to the murine models, IL-12 alone is not suffi-
cient to induce IFNγ expression, but requires the addition of other
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innate cytokines, such as IL-18 (12). The ability to respond to IL-
12 plus IL-18 is similar to that of NK cells (61), and implicates
MAIT cells in a range of infectious and non-infectious inflamma-
tory diseases. Furthermore, signaling via toll-like receptors (TLR)
is able to drive the expression of a range of pro-inflammatory
cytokines from professional APCs, which can activate MAIT cells
(Figure 1) (12, 62). We have shown that TLR8 agonists are particu-
larly potent stimulators of IL-12 and IL-18 secretion, and therefore
capable of driving MAIT cell IFNγ expression (12, 62). Thus,
this suggests that in addition to their anti-bacterial role, MAIT
cells may play an important role in anti-viral responses, and this
may also provide a mechanism that explains their involvement
in other pro-inflammatory settings such as experimental autoim-
mune encephalomyelitis, multiple sclerosis, inflammatory bowel
disease, psoriasis, and arthritis (15, 16, 54, 63, 64).
MAIT CELL CYTOTOXICITY
How MAIT cells affect their anti-bacterial function remains poorly
defined. Upon activation, MAIT cells are able to produce several
cytokines, including IFNγ, TNFα, and IL-17 (17, 24). In addi-
tion, it has recently been demonstrated that MAIT cells are also
cytotoxic. Le Bourhis et al. reported that MAIT cells can recog-
nize epithelial cells (HeLa cells) infected with Shigella flexneri but
not S. enterica serovar Typhimurium (30). Consistent with this,
MAIT cells were able to kill HeLa cells infected with S. flexneri
but not S. enterica serovar Typhimurium. This cytotoxicity was
dependent upon MR1 and was evident in HeLa cells expressing
endogenous levels of MR1. No reactivity was seen with a Salmo-
nella pathogenicity island 1 (SpI-1)-deleted strain of S. enterica
serovar Typhimurium (SpI-1 is required for invasion). Similarly,
MAIT cell activation and cytotoxicity was not seen with a SpI2-
deleted strain of S. enterica serovar Typhimurium. Therefore, the
virulence factors that prevent MR1 loading remain to be defined.
The authors’ suggestion was that Salmonella avoids detection as it
resides in vacuoles and prevents fusion with the lysosome, while
Shigella escapes to the cytoplasm. Indeed, invasion by Shigella was
important as HeLa cells infected with a DMxiD strain were unable
to efficiently activate MAIT cells. In vivo activation (determined
by HLA-DR expression) and decreased frequency of MAIT cells
in blood was observed in human beings after oral challenge with
an attenuated strain of S. dysenteriae suggesting that MAIT cells
responded to S. dysenteriae in vivo.
Recently, Kurioka et al. described increased cytotoxic potential
of MAIT cells after activation (13). These cytotoxic, or “licensed,”
MAIT cells displayed upregulation of granzyme B, normally not
expressed in resting MAIT cells, and enhanced perforin expres-
sion, which is low in resting MAIT cells (13). The licensed MAIT
cells displayed an increased capacity to kill cognate-target cells,
and maintained this phenotype even after several rounds of
proliferation.
A ROLE FOR MAIT CELLS IN THE CONTROL OF SALMONELLA
INFECTION
The role of MAIT cells in Salmonella infection remains to be
defined. As discussed above, MAIT cells can be activated by Sal-
monella sp. in vitro (8, 11, 25). MAIT cells activated by Salmonella
sp. produce IFNγ and TNFα; these cytokines have been shown
to be important in the control of Salmonella infection (65). In
addition, MAIT cells can secrete IL-17 in response to stimula-
tion with E. coli (55). IL-17 has recently been suggested to be
critical in preventing the dissemination of Salmonella. In IL-17
receptor-deficient mice, increased systemic dissemination of S.
enterica serovar Typhimurium was seen (66). Furthermore, in SIV-
infected rhesus macaques, increased dissemination of S. enterica
serovar Typhimurium was seen, which was associated with loss of
Th17 cells and the IL-17 response from the ileum (66). Therefore,
along with the loss of Th17 cells (67), the loss of MAIT cells in
HIV infection may contribute to the increased susceptibility to
disseminated non-typhoidal Salmonella infection (68).
Mucosal-associated invariant T-cells may also contribute to the
control of Salmonella infection through cytotoxic activity. Cyto-
toxic T-cells are important in the clearance of Salmonella infection
(69). However, MAIT cells are unable to kill HeLa cells, an epithe-
lial cell line, infected with Salmonella (69). This may be because
live Salmonella sp. is able to avoid MR1 containing compartments
by preventing phagosome-lysome fusion (70). Future investiga-
tions with live Salmonella sp. may help elucidate the MR1 loading
pathway/s, and subsequent activation of MAIT, revealing potential
therapeutic targets.
The low numbers of MAIT cells in common laboratory mouse
strains has hampered the study of the role MAIT cells in response
to Salmonella infection. Therefore, a robust murine model is
required to investigate the role of MAIT cells in the control of
Salmonella infection.
MAIT CELLS IN INFECTIOUS DISEASE
The role of MAIT cells in human disease has not been fully assessed
due to the difficulties of obtaining tissue samples. However, there
are a number of interesting associations between the frequency of
MAIT cells within peripheral blood and disease. During active M.
tuberculosis infection, MAIT cells numbers are lower in peripheral
blood compared to healthy controls (2, 25, 71, 72). Consistent with
these findings, Grimaldi et al. looked at MAIT cell numbers in crit-
ically ill septic and non-septic patients (14). They observed that
all critically ill patients studied, including those with severe bac-
terial or viral infections and those with non-infective illness, had
low MAIT cell counts compared to healthy controls. This was least
pronounced in individuals with severe viral infections, and most
striking in individuals infected with bacteria other than Streptococ-
cus species (14). This suggests that the loss of MAIT cells from the
periphery could be due, in part, to compartmentalization during
disease (2, 25). Interestingly, however, the authors also observed
that those individuals with persistent MAIT cell depletion at day 4
post-admission were at increased risk for subsequent nosocomial
infections. Therefore, MAIT cell exhaustion or death, two mech-
anisms proposed to occur in HIV (see below), may contribute to
this phenotype.
In both HCV and HIV, MAIT cells are depleted from the blood
(17, 31, 55). During HCV infection, the loss of peripheral MAIT
cells is potentially due to their relocation to the liver (17). More-
over, the frequency of IFNγ and IL-17 dual-expressing CD8+
T-cells in the liver, a proxy for MAIT cells, was inversely correlated
with the fibrosis score, suggesting that they either play a protec-
tive role during HCV infections, or that they are progressively lost
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from the liver with increasing fibrosis. This might contribute to
the higher rates of bacteremia seen in individuals with cirrhosis
(45, 73, 74).
In HIV infection, the loss of CD161++ MAIT cells from blood
occurs early during infection and persists despite otherwise suc-
cessful anti-retroviral therapy (31, 55, 71, 75, 76), although the
nature of this perturbation is unclear. Cosgrove et al. reported that
MAIT cells, defined as CD161++ CD8+ T-cells by flow cytometry,
were depleted as a proportion of the CD8+ T-cell population in
blood (55). They proposed that this depletion was due, at least in
part, to activation induced cell death from overstimulation sec-
ondary to microbial translocation. While Leeansyah et al. also
observed a decrease in size of the CD161++Vα7.2+ population,
they suggested that this was due to downregulation of CD161 and
functional exhaustion of MAIT cells (31). In support of this, they
noted an increase in frequency of CD161-Vα7.2+ T-cells as a pro-
portion of CD3+ T-cells. Importantly, the antibody against Vα7.2
used in these studies is not specific for the canonical MAIT cell
TCR (33). Therefore, the recently described MR1 tetramer will be
useful to determine whether the CD161-Vα7.2+ T-cells seen in
HIV infection are MAIT cells or not (8). Interestingly, in healthy
donors, MR1 tetramer does not bind the CD161-Vα7.2+ T-cell
population.
MAIT CELLS IN INFLAMMATORY DISEASE
In addition to their anti-microbial activity, MAIT cells have also
been implicated in a range of pro-inflammatory settings. Serriari
et al. observed that individuals with inflammatory bowel diseases
had lower numbers of circulating MAIT cells compared to con-
trols (54), as seen during bacterial and viral infections (2, 17, 25,
54, 71). However, within individuals, the frequencies of MAIT cells
were increased within inflamed tissues compared to healthy tissue,
suggesting recruitment of MAIT cells from the blood to sites of
inflammation. This is a theme consistent in other inflammatory
diseases such as psoriasis, rheumatoid arthritis, multiple sclero-
sis, and experimental autoimmune encephalomyelitis (15–17, 63,
77). Interestingly, CD56−MAIT cells have been observed infiltrat-
ing kidney and brain tumors, implying a potential role in tumor
immunity (78).
Overall, these studies in human disease demonstrate that MAIT
cells are a population of innate-like cells that rapidly translocate
to sites of inflammation, regardless of whether the inflammation
is due to bacterial infection or to other pro-inflammatory stimuli.
WHAT THE FUTURE HOLDS FOR MAIT CELL RESEARCH
Through the use of tools such as Salmonella, our understand-
ing of MAIT cell functions has increased rapidly over the last
5 years. However, there are still a number of important questions
to be answered. Are there other ligands presented by MR1? Is
there an endogenous ligand within the thymus for MAIT cell
selection? How is MR1 regulated? What are the relative roles of
TCR-dependent and TCR-independent triggering of MAIT cells
in host defense? Understanding what MR1 presents and how it is
regulated will be critical for understanding where and when MAIT
cells have a definitive role in disease. What role MAIT cells play
during human disease, in both infectious and autoimmune set-
tings also needs to be addressed. Although it is important to study
human disease, much will be learnt from animal models. Under-
standing how MAIT cells are regulated will potentially allow their
in vivo manipulation for a positive outcome. Given the rise of
antibiotic resistant bacteria, as highlighted by the recent WHO
report (April 2014) future prophylactic and therapeutic strategies
that harness the anti-bacterial potential of MAIT cells may be
particularly important (79, 80).
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